The top story in endocrinology this week was the announcement of the potential development of a vaccine to prevent type 1 diabetes following celiac disease research.
Other popular stories included findings that vitamin D supplementation may improve metabolic syndrome parameters in children with obesity, the FDA approval of testosterone self-injection for hypogonadism in men, research indicating that ultra-rapid insulin improves postprandial glucose levels in type 1 and type 2 diabetes and a study that found that an artificial pancreas improves time-in-range glucose values compared with pump therapy.
Diabetes vaccine may follow from celiac disease research
The venture philanthropy organization JDRF T1D Fund is investing in ImmusanT, a clinical-stage company attempting to develop a vaccine to prevent type 1 diabetes following on its peptide immunotherapy program for celiac disease, the two entities announced in a press release. Read more.
Vitamin D supplementation may improve metabolic syndrome parameters in children with obesity
Children with overweight and obesity assigned to receive vitamin D supplementation for 1 year experienced decreases in BMI and fat mass and a rise in HDL cholesterol vs. similar children assigned to placebo, according to study findings presented at the European Society for Paediatric Endocrinology annual meeting. Read more.
FDA approves testosterone self-injection for hypogonadism in men
The FDA on Monday approved Antares Pharma’s testosterone enanthate injection Xyosted for testosterone replacement therapy in men with primary hypogonadism or hypogonadotropic hypogonadism, the company announced in a press release. Read more.
Ultra-rapid insulin improves postprandial glucose levels in type 1, type 2 diabetes
An ultra-fast-acting mealtime insulin — dubbed Ultra Rapid Lispro, or URLi — reduced HbA1c as well as insulin lispro and significantly improved postprandial glucose levels in adults with type 1 and type 2 diabetes, according to a press release from Eli Lilly. Read more.
Artificial pancreas improves time-in-range glucose values vs. pump therapy
A cohort of patients with type 1 diabetes, including children as young as age 6 years, treated with insulin pump therapy experienced a 10% improvement in time spent in the recommended glycemic range when randomly assigned to 12 weeks using a hybrid closed-loop insulin delivery system, according to findings published in The Lancet and presented at the European Association for the Study of Diabetes annual meeting. Read more.